Although Claritas News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Although claritas. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Although Claritas Today - Breaking & Trending Today

Claritas Announces Approval from OTC to Up-List to OTCQB

SAN FRANCISCO, CA and TORONTO, ON, April 07, 2022 Claritas Pharmaceuticals, Inc. is pleased to announce that it has obtained approval from the OTC Markets Group for listing of its Common. | April 7, 2022 ....

Robert Farrell , Exchange Commission , Claritas Pharmaceuticals Inc , Company Or Claritas , Claritas Pharmaceuticals , Globenewswire Inc , Common Shares , Although Claritas , Claritas Pharmaceuticals Stock Exchange , Press Release , Ts Kly Ca1806341071 ,

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS

Claritas Announces Option to Acquire Rights to Novel Drug for Treatment of COVID-19 Related ARDS
teletrader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from teletrader.com Daily Mail and Mail on Sunday newspapers.

Sao Paulo , Rio De Janeiro , Estado Do Rio , Robert Farrell , Rezaa Ghiladi , Jun Wang , Jingrui Jiang , Shenghan Lai , Chuan Liu , Sara Akerstrom , Mehrdad Mousavi Jazi , Wanyi Fang , Mikael Leijon , Jonas Klingstrom , Ali Mirazimi , Brazilian Health Regulatory Agency , Claritas Pharmaceuticals Inc , Company Or Claritas , Claritas Pharmaceuticals , Venture Exchange , Regulation Services Provider , Biozeus Biopharmaceuticals , Clinical Study , Clarita President , Induces Expression , Nitric Oxide Synthase ,

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax ...

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax ...
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

South Australia , United States , Robert Farrell , Andrew Salzman , Company Australian , Company Or Claritas , Company The Common , Claritas Pharmaceuticals , Obsidian Global Partners , Company Common , Australian Taxation Office , Claritas Pharmaceuticals Inc , Venture Exchange , Regulation Services Provider , B Riley Financial Inc , Australian Tax Office , Australian Tax , Aggregate Proceeds , Loan Amount , First Tranche Debenture , Tranche Maturity , Common Shares , Tranche Conversion , Any Common Shares , Principal Amount , Tranche Amortization ,

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107

Claritas Announces Proposed Financing with Obsidian Global GP, LLC, Receipt of Australian Tax Credit, and Start of Phase 1 Clinical Study of R-107
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

South Australia , United States , Robert Farrell , Andrew Salzman , Company Australian , Company Or Claritas , Company The Common , Claritas Pharmaceuticals , Obsidian Global Partners , Company Common , Australian Taxation Office , Claritas Pharmaceuticals Inc , Venture Exchange , Regulation Services Provider , B Riley Financial Inc , Australian Tax Office , Australian Tax , Aggregate Proceeds , Loan Amount , First Tranche Debenture , Common Shares , Any Common Shares , Principal Amount , Tranche Amortization , First Tranche Amortization Payments , First Tranche Amortization ,

Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Claritas Pharmaceuticals, Inc.April 21, 2021 GMT
SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd (“CMAX”) to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of the Company’s novel, liquid, nitric oxide-releasing drug, R-107. ....

South Australia , United States , South Korea , Robert Farrell , Funding For The Company Phase , Company Or Claritas , Claritas Pharmaceuticals , Clinical Research Pty Ltd , Salzman Group , Claritas Pharmaceuticals Inc , Venture Exchange , Regulation Services Provider , Australian Tax Office , Research Pty Ltd , Nitric Oxide Releasing , License Agreement , Good Clinical Practice , Data Intended , Support Follow On Studies , Although Claritas , தெற்கு ஆஸ்திரேலியா , ஒன்றுபட்டது மாநிலங்களில் , தெற்கு கொரியா , ராபர்ட் ஃப்யாரெல் , சால்ஸ்மேன் குழு , துணிகர பரிமாற்றம் ,